...
首页> 外文期刊>Medicine. >The laser combined with intravitreal injection of ranibizumab for treatment of macular edema secondary to branch retinal vein occlusion
【24h】

The laser combined with intravitreal injection of ranibizumab for treatment of macular edema secondary to branch retinal vein occlusion

机译:激光结合玻璃纤维素注射Ranibizumab,用于治疗次级分支视网膜静脉闭塞的黄斑水肿

获取原文

摘要

BACKGROUND:At present, laser is regarded as an effective treatment for macular edema secondary to branch retinal vein occlusion. With the breakthrough of anti-vascular endothelial growth factor drugs in ophthalmology clinical research, the intravitreal injection of ranibizumab is widely applied, but both methods have their limitations, so some clinical studies have combined and applied them together. However, the clinical results are inconsistent and controversial, and there is no relevant system evaluation for the laser combined with intravitreal injection of ranibizumab for treatment of macular edema secondary to branch retinal vein occlusion now.OBJECTIVE:Meta analysis is used to analyze and evaluate the effectiveness and safety of the laser combined with intravitreal injection of ranibizumab for treatment of macular edema secondary to branch retinal vein occlusion.METHOD:CNKI, VIP, WANFANG, China Biology Medicine disc, Web of Science, PubMed, Embase, Cochrane Library have used random controlled clinical trial of laser combined with intravitreal injection of ranibizumab for treatment of macular edema secondary to branch retinal vein occlusion from the establishment of the database to October 2020. Two researchers conducted independent screening, quality assessment and data extraction for the literatures, and used RevMan5.3 to conduct Meta analysis for the included literatures.RESULT:The research has evaluated the effectiveness and safety of the laser combined with intravitreal injection of ranibizumab for treatment of macular edema secondary to branch retinal vein occlusion through the aspects of the best corrected visual acuity 6 months after operation, macular center thickness and the incidence of adverse reactions such as elevated intraocular pressure, endophthalmitis, vitreous hemorrhage and cataract.CONCLUSION:Laser combined with intravitreal injection of ranibizumab for treatment of macular edema secondary to branch retinal vein occlusion has good effect, and the research has provided reliable evidence for the use of clinical treatment of the laser combined with intravitreal injection of ranibizumab for treatment of macular edema secondary to branch retinal vein occlusion.Copyright ? 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
机译:背景:目前,激光被认为是用于分支视网膜静脉闭塞的次级黄斑水肿的有效治疗。随着抗血管内皮生长因子药物在眼科临床研究中的突破,含有爬气液注射的Ranibizumab被广泛应用,但两种方法都有其局限性,因此一些临床研究已经组合并将它们施加在一起。然而,临床结果是不一致的和争议的,并且对于术治疗术治疗术治疗二级的术治疗术治疗近代静脉闭塞的激光,临床结果不一致。目的:Meta分析用于分析和评估激光的有效性和安全性联合Ranibizumab治疗Mallvumizuma用于治疗分支视网膜静脉闭塞。方法:CNKI,VIP,万方,中国生物医学椎间盘,科学网,PUBMED,EMBASE,Cochrane图书馆所用激光的受控临床试验与玻璃腹注射Ranibizumab治疗二次分支后静脉闭塞治疗数据库到2020年10月。两位研究人员对文献进行了独立的筛选,质量评估和数据提取,并使用Revman5进行了独立的筛选,质量评估和数据提取。 .3为包括的文献进行元分析研究研究已经评估了激光器的有效性和安全性联合Ranibizumab的玻璃体硝基脲注射治疗,用于治疗次级的微型水肿,通过​​操作,黄斑中心厚度和发病率最佳矫正视力的各个方面。不良反应,如升高的眼内压,内膜炎,玻璃体炎,玻璃体腐殖和白乳糖。结合:激光结合玻璃纤维素注射Ranibizumab用于治疗二次分支后静脉闭塞的黄斑水肿具有良好的效果,并且该研究为使用提供了可靠的证据激光临床治疗结合玻璃腹注射RANIBizumab治疗MATRAMIBIZMAS中的分支视网膜静脉闭塞。 2021提交人。由Wolters Kluwer Health,Inc。出版

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号